{"id":514368,"date":"2021-07-19T07:36:07","date_gmt":"2021-07-19T11:36:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/"},"modified":"2021-07-19T07:36:07","modified_gmt":"2021-07-19T11:36:07","slug":"swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/","title":{"rendered":"SWK Holdings Provides Portfolio Update Highlighting Recent Achievements"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Second Quarter 2021 Financial Results to be Announced in August<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">DALLAS<\/span>, <span class=\"xn-chron\">July 19, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0SWK Holdings Corporation (Nasdaq: SWKH) (&#8220;SWK&#8221; or the &#8220;Company&#8221;), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the achievements of its portfolio and partner companies during the first half of 2021.<\/p>\n<p>&#8220;We are pleased with the latest additions to our royalty and debt portfolio, as well as the advances reported by our partner companies over the past several months,&#8221; stated <span class=\"xn-person\">Winston Black<\/span>, Chairman and CEO of SWK. &#8220;Collectively, life sciences companies are making a strong recovery from the disruption and supply chain issues that temporarily impacted the industry last year during the initial months of the COVID-19 pandemic. Our continued strong portfolio performance validates an approach to investing in the potential of small and mid-sized life sciences companies with commercial products, backed by strong intellectual property protection, that fill unmet demands within the healthcare system. This is the engine that will drive SWK&#8217;s shareholder value creation.&#8221;<\/p>\n<p>SWK provides funding that supports growth opportunities for small and mid-sized life sciences companies through the creation of unique financing structures. These deals include structured debt, traditional royalty monetization, synthetic royalty transactions and asset purchases, and typically range in size from <span class=\"xn-money\">$5 million<\/span> to <span class=\"xn-money\">$20 million<\/span>, a market segment often ignored by other structured finance companies.<\/p>\n<p>Mr. Black continued, &#8220;We are also encouraged by the progress at our subsidiary, Enteris BioPharma. Having completed the expansion of the company&#8217;s manufacturing facility, CEO <span class=\"xn-person\">Rajiv Khosla<\/span> and his team announced in <span class=\"xn-chron\">May 2021<\/span> the launch of its CDMO business segment and continues to pursue business development opportunities for its Peptelligence\u00ae and ProPerma\u2122 technologies. Enteris continues to build value for our shareholders, as illustrated by the recently announced <span class=\"xn-money\">$10 million<\/span> milestone payment from Cara Therapeutics for the ongoing development of Oral KORSUVA\u2122, which was developed with Enteris&#8217; Peptelligence. Oral KORSUVA\u2122 is now the subject of four separate clinical programs, including an anticipated Phase 3 trial for the treatment of pruritus in patients with stage III-IV chronic kidney disease. We anticipate additional milestone payments over the next several quarters, subject to the achievement of development milestones.&#8221;<\/p>\n<p>\n        <b>Enteris BioPharma, Inc.<br \/><\/b>In <span class=\"xn-chron\">August 2019<\/span>, SWK Holdings acquired Enteris BioPharma, a biotechnology company developing innovative oral formulations of hard-to-dose peptide- and small molecule-based therapies built around its proprietary drug delivery technologies, Peptelligence and ProPerma.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">May 2021<\/span>, Enteris announced the launch of its CDMO business segment. An expanded manufacturing facility with a high potency API (HPAPI) suite allows Enteris to provide bench-to-market services, including the development, manufacture, testing and release of Phase 3 clinical trial supplies, and commercial production. <\/li>\n<li>Enteris&#8217; work with Cara Therapeutics on its first-in-class KOR agonist, CR845, commonly known as Oral KORSUVA, continued to progress. <\/li>\n<ul type=\"circle\">\n<li>In <span class=\"xn-chron\">June 2021<\/span>, Enteris received a <span class=\"xn-money\">$10 million<\/span> milestone payment from Cara Therapeutics, of which Enteris was entitled to keep <span class=\"xn-money\">$3.6 million<\/span> pursuant to the terms of SWK&#8217;s acquisition of Enteris. <\/li>\n<li>In <span class=\"xn-chron\">April 2021<\/span>, Cara completed an End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA). Cara has announced that it expects to initiate a Phase 3 trial by year end 2021 for Oral KORSUVA in patients with non-dialysis dependent (NDD) chronic kidney disease (CKD-aP). <\/li>\n<li>To date, Enteris has received three milestone payments totaling <span class=\"xn-money\">$15 million<\/span>, of which it was entitled to keep <span class=\"xn-money\">$6.9 million<\/span>.<\/li>\n<\/ul>\n<\/ul>\n<p>\n        <b>Transactions Completed During 2021<\/b>\n      <\/p>\n<p>\n        <b>TRIO Healthcare Ltd.\u00a0\u00a0 <br \/><\/b>In <span class=\"xn-chron\">July 2021<\/span>, SWK closed a <span class=\"xn-money\">$9.5 million<\/span> financing with Trio Healthcare to support the company&#8217;s UK and international launch of its innovative stoma bag, Genii, of which <span class=\"xn-money\">$5.1 million<\/span> was advanced at close.\u00a0 The <span class=\"xn-money\">$9.5 million<\/span> financing follows SWK&#8217;s <span class=\"xn-chron\">October 2020<\/span> royalty transaction with Trio.<\/p>\n<p>\n        <b>Ideal Implant, Inc. <br \/><\/b>In <span class=\"xn-chron\">April 2021<\/span>, SWK closed a <span class=\"xn-money\">$5 million<\/span> synthetic royalty transaction with Ideal Implant, a medical device company focused on the aesthetics space.\u00a0\u00a0\u00a0 <\/p>\n<p>\n        <b>Sincerus Pharmaceuticals, Inc. <br \/><\/b>In <span class=\"xn-chron\">March 2021<\/span>, Sincerus Pharmaceuticals, a <span class=\"xn-money\">503B<\/span> compounding pharmacy focused on dermatology customers, closed a <span class=\"xn-money\">$9 million<\/span> financing with SWK.\u00a0 The funds are partially earmarked for a new U.S.-based customized medication manufacturing facility. SWK advanced \u00a0$7.1 million at the close of the financing. In <span class=\"xn-chron\">May 2021<\/span>, SWK advanced an additional <span class=\"xn-money\">$0.7 million<\/span> and in <span class=\"xn-chron\">June 2021<\/span>, Sincerus achieved performance milestones and drew the final <span class=\"xn-money\">$1.9 million<\/span>.\u00a0 <\/p>\n<p>\n        <b>Borrower Liquidity Events<\/b>\n      <\/p>\n<p>In <span class=\"xn-chron\">April 2021<\/span>, two borrowers, Tenex Health, Inc., and Harrow Health, Inc., experienced liquidity events and subsequently repaid loans from SWK. SWK realized a cumulative 1.5x multiple on invested capital (MOIC) and will record the gains on these repayments when it reports financial results for the quarter ended <span class=\"xn-chron\">June 30, 2021<\/span>. SWK continues to hold warrants in Harrow Health.<\/p>\n<p>\n        <b>SWK Holdings Portfolio Updates<\/b>\n      <\/p>\n<p>\n        <b>4Web, Inc.<br \/><\/b>4Web is a privately held medical-device company, based in <span class=\"xn-location\">Frisco, TX<\/span>, that utilizes a proprietary truss implant technology to develop and market spinal implants. In <span class=\"xn-chron\">June 2019<\/span>, 4Web entered a <span class=\"xn-money\">$20 million<\/span> structured credit agreement with SWK.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">May 2021<\/span>, SWK signed an amendment to its credit agreement with 4Web and subsequently advanced an additional <span class=\"xn-money\">$2.25 million<\/span> to support the company&#8217;s ongoing growth. <\/li>\n<li>In <span class=\"xn-chron\">March 2021<\/span>, 4Web received approval from the FDA to market its lumbar spine plating solution in the U.S. The commercial launch followed in <span class=\"xn-chron\">May 2021<\/span>.<\/li>\n<\/ul>\n<p>\n        <b>Acerus Pharmaceuticals Corporation<br \/><\/b>Acerus Pharmaceuticals is a Canadian specialty pharmaceutical company with a flagship commercial product Natesto\u00ae for the treatment of men with low levels of endogenous testosterone. Acerus entered an <span class=\"xn-money\">$11 million<\/span> structured credit agreement with SWK in <span class=\"xn-chron\">October 2018<\/span>.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">June 2021<\/span>, a leading pharmacy benefit manager designated Natesto as a &#8220;Preferred Brand&#8221; on its National Preferred Drug List. <\/li>\n<li>In <span class=\"xn-chron\">May 2021<\/span>, Acerus entered a three-year agreement with Amneal Pharmaceuticals to co-promote Natesto in the U.S. endocrinology market. <\/li>\n<li>In <span class=\"xn-chron\">April 2021<\/span>, Acerus closed a <span class=\"xn-money\">$15 million<\/span> subordinated secured loan facility with First Generation Capital, Inc. The loan is subordinate to the company&#8217;s existing loan agreement with SWK. <\/li>\n<\/ul>\n<p>\n        <b>Assertio Therapeutics, Inc. \u00a0\u2013 Cambia\u00ae<br \/><\/b>Cambia is a nonsteroidal, anti-inflammatory drug (NSAID) developed to treat migraine attacks in adults. In <span class=\"xn-chron\">July 2014<\/span>, SWK paid <span class=\"xn-money\">$4.0 million<\/span> to acquire 25% of the royalty stream and in <span class=\"xn-chron\">December 2015<\/span>, acquired an additional 25% of the royalty stream for <span class=\"xn-money\">$4.5 million<\/span>.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">May 2021<\/span>, Assertio Holdings partnered with Cove, a leading migraine telemedicine platform, to launch a direct-to-patient digital campaign to increase accessibility to Cambia. <\/li>\n<\/ul>\n<p>\n        <b>Biolase, Inc.<\/b><br \/>\n        <br \/>Biolase is a global leader in dental lasers. In <span class=\"xn-chron\">November 2018<\/span>, Biolase entered a <span class=\"xn-money\">$15 million<\/span> structured credit arrangement with SWK.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">May 2021<\/span>, Biolase released preliminary first quarter financial results. Net revenue rose \u00a070% to <span class=\"xn-money\">$8.1 million<\/span>. Biolase indicated that the jump in revenue reflects, in part, pent up demand as dental offices in the U.S. and abroad continue to reopen and patient volumes return to near pre-COVID-19 levels.<\/li>\n<\/ul>\n<p>\n        <b>Emergent BioSolutions, Inc. &#8212; Narcan\u00ae<br \/><\/b>Narcan, a nasal spray formulation of naloxone, is the only FDA-approved needle-free emergency opioid overdose reversal drug approved by the FDA. In <span class=\"xn-chron\">December 2016<\/span>, SWK paid <span class=\"xn-money\">$17.5 million<\/span> to Opiant Pharmaceuticals to acquire certain royalties associated with Narcan sales.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">April 2021<\/span>, the FDA approved a higher dose Narcan nasal spray product that delivers 8 mg into the nasal cavity. The FDA had previously approved 2 mg and 4 mg products. <\/li>\n<li>Narcan sales for the first quarter of 2021, reported in April, totaled <span class=\"xn-money\">$74.2 million<\/span>. Emergent Biosciences has guided it expects full-year 2021 sales of Narcan to range between <span class=\"xn-money\">$305 million<\/span> and <span class=\"xn-money\">$325 million<\/span>.<\/li>\n<\/ul>\n<p>\n        <b>Epica International, Inc.<br \/><\/b>Epica International designs, develops and distributes medical imaging platforms and robotic systems for use in human, animal and industrial markets. Epica entered a <span class=\"xn-money\">$14 million<\/span> structured credit arrangement with SWK in <span class=\"xn-chron\">July 2018<\/span>.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">May 2021<\/span>, Epica announced a new corporate headquarters and operation in <span class=\"xn-location\">Spartanburg County, S.C.<\/span><\/li>\n<li>The company also began commercialization of its FDA <span class=\"xn-money\">510k<\/span> approved SeeFactor CT3, a mobile imaging platform consisting of three integrated imaging systems (CT, Fluoroscopy and Digital Radiography).<\/li>\n<\/ul>\n<p>\n        <b>Eton Pharmaceuticals, Inc.<br \/><\/b>Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing innovative products utilizing the FDA&#8217;s 505(b)(2) regulatory pathway. In <span class=\"xn-chron\">November 2019<\/span>, Eton entered a <span class=\"xn-money\">$10 million<\/span> structured credit agreement with SWK, which was amended in <span class=\"xn-chron\">August 2020<\/span> to increase the facility size to <span class=\"xn-money\">$15 million<\/span>.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">June 2021<\/span>, Eton received FDA approval for Rezipres\u00ae, a ready-to-use hospital ephedrine hydrochloride injection, to treat clinically important hypotension occurring in the setting of anesthesia.\u00a0 <\/li>\n<li>Also in June, Eton acquired U.S. and Canadian rights to ZENO\u00ae hydrocortisone autoinjector, a needleless device under development by Crossject as a rescue treatment for adrenal crisis, for which it expects to submit a New Drug Application (NDA) to the FDA in 2023 and plans to request Orphan Drug Designation.<\/li>\n<\/ul>\n<p>\n        <b>Iluvien\u00ae Royalty<br \/><\/b>In <span class=\"xn-chron\">December 2020<\/span>, SWK paid <span class=\"xn-money\">$16.5 million<\/span> to acquire royalties payable to EyePoint Pharmaceuticals under its license agreement with Alimera Sciences for Iluvien, a treatment for diabetic macular edema.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">April 2021<\/span>, Alimera granted an exclusive license to Ocumension Therapeutics to develop and commercialize Iluvien in the greater <span class=\"xn-location\">China<\/span> territory and other western Pacific countries under Ocumension&#8217;s own distinct trademark. <\/li>\n<li>Alimera received a <span class=\"xn-money\">$10 million<\/span> upfront payment and could receive up to <span class=\"xn-money\">$89 million<\/span> in additional sales-based milestone payments. Ocumension also made a <span class=\"xn-money\">$10 million<\/span> equity investment in Alimera.<\/li>\n<\/ul>\n<p>\n        <b>Ideal Implant<br \/><\/b>Founded in 2006, the privately held medical device company is focused on the aesthetics space, specifically the development and sale of a saline breast implant containing a novel internal structure that gives it the natural feel and look of silicone gel implants. In <span class=\"xn-chron\">April 2021<\/span>, SWK advanced <span class=\"xn-money\">$5 million<\/span> for a synthetic royalty deal with Ideal Implant.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">June 2021<\/span>, Ideal Implant released 10-year FDA core clinical trial data indicating that the\u00a0 Ideal Implant Structured Breast Implant presents a substantially lower risk of rupture and deflation, compared to silicone gel implants. <\/li>\n<li>The data also showed a substantially lower risk of capsular contracture, a post-surgery complication where scar tissue forms around the implant. <\/li>\n<\/ul>\n<p>\n        <b>Misonix, Inc.<br \/><\/b>In\u00a0September 2019, Misonix, a provider of minimally invasive therapeutic ultrasonic medical devices, acquired Solsys Medical, LLC, a privately held regenerative medicine company. Misonix assumed Solsys&#8217; credit facility with SWK. Following the acquisition, SWK upsized its credit facility with Misonix to <span class=\"xn-money\">$30 million<\/span> to support the company&#8217;s growth objectives.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">May 2021<\/span>, Misonix reported a 2.5% increase in revenue during its fiscal third quarter to <span class=\"xn-money\">$18.3 million<\/span>. This marks a return to year-over-year revenue growth for the first time since the peak of the COVID-19 pandemic in <span class=\"xn-chron\">June 2020<\/span>.<\/li>\n<\/ul>\n<p>\n        <b>Sincerus Pharmaceuticals, Inc.<br \/><\/b>As a <span class=\"xn-money\">503B<\/span> compounding pharmacy, Sincerus provides customized prescription medicines to dermatologists for private labeling and dispensing at point of care. In <span class=\"xn-chron\">March 2021<\/span>, Sincerus closed a <span class=\"xn-money\">$9 million<\/span> financing with SWK.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">May 2021<\/span>, SWK advanced an additional tranche of <span class=\"xn-money\">$750,000<\/span> to support the company&#8217;s continued impressive growth. <\/li>\n<li>In <span class=\"xn-chron\">June 2021<\/span>, Sincerus achieved sales milestone required to access the <span class=\"xn-money\">$1.9 million<\/span> final loan tranche, which was funded that same month.<\/li>\n<\/ul>\n<p>\n        <b>Tissue Regeneration Therapeutics <br \/><\/b>Tissue Regeneration Therapeutics is focused on developing a portfolio of skin care products and cell-based therapies using mesenchymal stromal\/stem cells harvested using its patented human umbilical cord tissue technology platforms. The <span class=\"xn-location\">Toronto<\/span>-based life sciences company entered into a <span class=\"xn-money\">$3.3 million<\/span> royalty purchase agreement with SWK in <span class=\"xn-chron\">June 2013<\/span>. In <span class=\"xn-chron\">August 2020<\/span>, the royalty was terminated in exchange for common equity and a convertible note.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">June 2021<\/span>, Tissue Regenerative Therapeutics launched a new e-commerce website for its newly launched cosmetic product, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3231691-1&amp;h=813229495&amp;u=https%3A%2F%2Ftrtcellular.com%2F&amp;a=TRT+CELLULAR\" rel=\"nofollow noopener\">TRT CELLULAR<\/a>.<\/li>\n<\/ul>\n<p>\n        <b>Veru, Inc. <br \/><\/b>Veru is a biopharmaceutical company focused on oncology therapeutics. Through Veru&#8217;s Female Health Company division, the company also markets the FC2 &#8220;female condom.&#8221; In 2018, Veru completed a <span class=\"xn-money\">$10 million<\/span> &#8220;synthetic royalty financing&#8221; on FC2 sales with SWK.<\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">March 2021<\/span> Veru engaged Morgan Stanley &amp; Co. LLC as a financial advisor to assist the company and its management in pursuing strategic alternatives regarding its legacy FC2 Female Condom\u00ae \/ FC2 Internal Condom business (FHC Business). <\/li>\n<li>In <span class=\"xn-chron\">May 2021<\/span>, Veru reported a 34% increase in second quarter net revenues to <span class=\"xn-money\">$13.3 million<\/span>, driven largely by record high U.S. sales of FC2. <\/li>\n<\/ul>\n<p>\n        <b>About SWK Holdings: <br \/><\/b>SWK Holdings Corporation is a specialized finance company with a focus on the global healthcare sector. SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK&#8217;s business partners and its investors. SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. SWK also owns Enteris BioPharma, whose Peptelligence<sup>\u00ae<\/sup> and ProPerma\u2122 drug delivery technologies create oral formulations of peptide-based and BCS class II, III, and IV small molecules. With Enteris, SWK has the opportunity to grow its specialty finance business by actively building a wholly-owned portfolio of milestones and royalties through licensing activities. Additional information on the life science finance market is available on the Company&#8217;s website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3231691-1&amp;h=3043388972&amp;u=https%3A%2F%2Fwww.swkhold.com%2F&amp;a=www.swkhold.com.+\" rel=\"nofollow noopener\">www.swkhold.com. <\/a><\/p>\n<p>\n        <b>Safe Harbor Statement <br \/><\/b>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;look forward,&#8221; &#8220;intend,&#8221; &#8220;guidance,&#8221; &#8220;future&#8221; or similar expressions are forward-looking statements. Because these statements reflect SWK&#8217;s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption &#8220;Risk Factors&#8221; and elsewhere in SWK&#8217;s Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company&#8217;s future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company&#8217;s actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise<b>.<\/b><\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA46970&amp;sd=2021-07-19\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-301336193.html\">https:\/\/www.prnewswire.com\/news-releases\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-301336193.html<\/a><\/p>\n<p>SOURCE  SWK Holdings Corporation<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA46970&amp;Transmission_Id=202107190733PR_NEWS_USPR_____LA46970&amp;DateId=20210719\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Second Quarter 2021 Financial Results to be Announced in August PR Newswire DALLAS, July 19, 2021 \/PRNewswire\/ &#8212;\u00a0SWK Holdings Corporation (Nasdaq: SWKH) (&#8220;SWK&#8221; or the &#8220;Company&#8221;), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the achievements of its portfolio and partner companies during the first half of 2021. &#8220;We are pleased with the latest additions to our royalty and debt portfolio, as well as the advances reported by our partner companies over the past several months,&#8221; stated Winston Black, Chairman and CEO of SWK. &#8220;Collectively, life sciences companies are making a strong recovery from the disruption and supply chain issues that temporarily impacted the industry last year during the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SWK Holdings Provides Portfolio Update Highlighting Recent Achievements&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-514368","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SWK Holdings Provides Portfolio Update Highlighting Recent Achievements - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SWK Holdings Provides Portfolio Update Highlighting Recent Achievements - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Second Quarter 2021 Financial Results to be Announced in August PR Newswire DALLAS, July 19, 2021 \/PRNewswire\/ &#8212;\u00a0SWK Holdings Corporation (Nasdaq: SWKH) (&#8220;SWK&#8221; or the &#8220;Company&#8221;), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the achievements of its portfolio and partner companies during the first half of 2021. &#8220;We are pleased with the latest additions to our royalty and debt portfolio, as well as the advances reported by our partner companies over the past several months,&#8221; stated Winston Black, Chairman and CEO of SWK. &#8220;Collectively, life sciences companies are making a strong recovery from the disruption and supply chain issues that temporarily impacted the industry last year during the &hellip; Continue reading &quot;SWK Holdings Provides Portfolio Update Highlighting Recent Achievements&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-19T11:36:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA46970&amp;sd=2021-07-19\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SWK Holdings Provides Portfolio Update Highlighting Recent Achievements\",\"datePublished\":\"2021-07-19T11:36:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\\\/\"},\"wordCount\":2265,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA46970&amp;sd=2021-07-19\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\\\/\",\"name\":\"SWK Holdings Provides Portfolio Update Highlighting Recent Achievements - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA46970&amp;sd=2021-07-19\",\"datePublished\":\"2021-07-19T11:36:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA46970&amp;sd=2021-07-19\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA46970&amp;sd=2021-07-19\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SWK Holdings Provides Portfolio Update Highlighting Recent Achievements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SWK Holdings Provides Portfolio Update Highlighting Recent Achievements - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/","og_locale":"en_US","og_type":"article","og_title":"SWK Holdings Provides Portfolio Update Highlighting Recent Achievements - Market Newsdesk","og_description":"Second Quarter 2021 Financial Results to be Announced in August PR Newswire DALLAS, July 19, 2021 \/PRNewswire\/ &#8212;\u00a0SWK Holdings Corporation (Nasdaq: SWKH) (&#8220;SWK&#8221; or the &#8220;Company&#8221;), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the achievements of its portfolio and partner companies during the first half of 2021. &#8220;We are pleased with the latest additions to our royalty and debt portfolio, as well as the advances reported by our partner companies over the past several months,&#8221; stated Winston Black, Chairman and CEO of SWK. &#8220;Collectively, life sciences companies are making a strong recovery from the disruption and supply chain issues that temporarily impacted the industry last year during the &hellip; Continue reading \"SWK Holdings Provides Portfolio Update Highlighting Recent Achievements\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-19T11:36:07+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA46970&amp;sd=2021-07-19","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SWK Holdings Provides Portfolio Update Highlighting Recent Achievements","datePublished":"2021-07-19T11:36:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/"},"wordCount":2265,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA46970&amp;sd=2021-07-19","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/","name":"SWK Holdings Provides Portfolio Update Highlighting Recent Achievements - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA46970&amp;sd=2021-07-19","datePublished":"2021-07-19T11:36:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA46970&amp;sd=2021-07-19","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA46970&amp;sd=2021-07-19"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swk-holdings-provides-portfolio-update-highlighting-recent-achievements-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SWK Holdings Provides Portfolio Update Highlighting Recent Achievements"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/514368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=514368"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/514368\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=514368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=514368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=514368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}